Profile data is unavailable for this security.
About the company
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
- Revenue in USD (TTM)0.00
- Net income in USD-108.30m
- Incorporated2004
- Employees118.00
- LocationKalvista Pharmaceuticals Inc55 Cambridge Pkwy Ste 901ECAMBRIDGE 02142-1234United StatesUSA
- Phone+1 (857) 999-0075
- Fax+1 (302) 531-3150
- Websitehttps://www.kalvista.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korro Bio Inc | 0.00 | -81.19m | 475.70m | 94.00 | -- | 2.72 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Absci Corp | 5.35m | -109.19m | 476.08m | 155.00 | -- | 1.98 | -- | 89.04 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Nkarta Inc | 0.00 | -116.20m | 478.48m | 150.00 | -- | 1.01 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 487.91m | 76.00 | -- | 2.28 | -- | 194.38 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Neurogene Inc | 0.00 | -39.03m | 488.06m | 91.00 | -- | 2.83 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Applied Therapeutics Inc | -477.00k | -193.56m | 489.06m | 26.00 | -- | 7.27 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 491.67m | 216.00 | -- | 3.05 | -- | 233.57 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Cabaletta Bio Inc | 0.00 | -76.87m | 491.94m | 118.00 | -- | 2.22 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 492.34m | 118.00 | -- | 4.56 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Aerovate Therapeutics Inc | 0.00 | -82.19m | 502.71m | 51.00 | -- | 5.36 | -- | -- | -3.03 | -3.03 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -71.09 | -- | -80.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 504.65m | 186.00 | -- | 1.95 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 508.42m | 709.00 | -- | 1.85 | -- | 2.91 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 510.42m | 42.00 | -- | 2.21 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| OmniAB Inc | 21.05m | -63.48m | 510.45m | 106.00 | -- | 1.69 | -- | 24.25 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Kalvista Pharmaceuticals Inc's reporting currency: US Dollar USD
49.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 31 Mar 2024 | 4.19m | 9.94% |
| Tang Capital Management LLCas of 31 Mar 2024 | 4.13m | 9.78% |
| Adage Capital Management LPas of 31 Mar 2024 | 2.58m | 6.10% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.23m | 5.29% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.65m | 3.92% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.46m | 3.47% |
| Saturn V Capital Management LLCas of 31 Mar 2024 | 1.44m | 3.42% |
| First Turn Management LLCas of 31 Mar 2024 | 1.18m | 2.80% |
| StemPoint Capital LPas of 31 Mar 2024 | 1.16m | 2.75% |
| DAFNA Capital Management LLCas of 31 Mar 2024 | 806.97k | 1.91% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
